U.S. Biotech Stock News

Fidelis Insurance Holdings (NYSE:FIHL) is back in focus after fresh data underscored a rapid expansion in net premiums and solid revenue growth forecasts, which reinforces the view that its market share gains are sticking. See our latest analysis for Fidelis Insurance Holdings. The steady fundamentals story is slowly feeding into the share price too, with an 8.96% 90 day share price return and a 10.25% one year total shareholder return suggesting momentum is quietly building around the...

Earlier this week, Camden Property Trust announced it will dual list its common stock on the new NYSE Texas while keeping its primary listing on the New York Stock Exchange and simultaneously raised its full‑year 2025 funds from operations guidance. The move underscores Camden’s emphasis on its Texas roots and multifamily leadership while signaling management’s confidence through higher expected cash-flow generation. Next, we’ll examine how the raised funds from operations guidance may...

General Mills recently reported fiscal second-quarter 2025 results showing sales of US$4,860.8 million and net income of US$413 million, down from the prior year but still ahead of analyst expectations on an adjusted basis. Alongside reaffirming its full-year outlook, the company emphasized price cuts, stepped-up product innovation, and ongoing share repurchases that have retired 73.10 million shares, or about 12.85% of its stock, since mid‑2022. With these earnings beating forecasts despite...

Earlier this month, Mizuho upgraded New Jersey Resources to Outperform, citing the company’s attractive valuation, strong fundamentals, and resilience to some regulatory pressures affecting other utilities. The bank also highlighted growth potential in New Jersey Resources’ Storage & Transportation and Clean Energy Ventures segments, alongside a solid balance sheet and limited equity needs, which together influenced investor perception despite mixed quarterly earnings. Next, we’ll examine...

Capital Clean Energy Carriers (CCEC) just sold 13 container vessels and lined up fresh financing to grow its LNG fleet, signaling a clear pivot toward energy transition shipping that could reshape its long term earnings mix. See our latest analysis for Capital Clean Energy Carriers. The market seems to be warming to that shift, with a roughly 15% year to date share price return and a strong five year total shareholder return above 200 percent. This suggests longer term momentum remains firmly...

FuelCell Energy (FCEL) just delivered a better than expected quarter, growing revenue, narrowing losses, and expanding its $1.19 billion backlog, all while leaning hard into power hungry data center demand. See our latest analysis for FuelCell Energy. That backdrop helps explain why FuelCell Energy’s recent earnings beat and data center push have not yet reversed the bigger picture. The 1 month share price return of 27.91% contrasts sharply with a 1 year total shareholder return of negative...

Lattice Semiconductor recently released version 8.0 of its Lattice sensAI solution stack, adding expanded model support, upgraded tools, and broader AI compatibility to help developers build low-power edge AI across industrial, automotive, and consumer systems. The inclusion of more pre-trained HMI, multi-object, and defect detection models, plus Python API integration and YAML-based automation, meaningfully lowers barriers to deploying customized AI at the far edge. We'll now examine how...

Recent upbeat commentary from Jim Cramer on DuPont de Nemours (DD) has put fresh attention on the stock, as he praised management, the new electronics spinoff, and the company’s focus on higher margin water and materials businesses. See our latest analysis for DuPont de Nemours. That upbeat narrative is landing just as DuPont’s 1 month share price return of about 9 percent contrasts sharply with a roughly 45 percent year to date decline, while multi year total shareholder returns remain...

Earlier this week, CRISPR Therapeutics drew attention as investors focused on an upcoming earnings report that is expected to show a sharp year-over-year decline in earnings and revenue, despite having an approved gene-editing therapy, Casgevy, on the market. The contrast between Casgevy’s slow initial uptake and the company’s solid balance sheet has sharpened debate over its near-term business momentum and longer-term positioning in gene editing. We’ll now examine how concerns about...

In recent commentary, Viavi Solutions has been highlighted as a key optics industry player, supplying critical test equipment that underpins reliable high-speed optical connectivity across the supply chain. The emphasis on Viavi’s essential role in validating 400G, 800G and 1.6T optics before deployment underscores its potential importance to long-term infrastructure upgrades and broader industry resilience. We’ll now examine how Viavi’s reinforced role in high-speed optics testing could...

Earlier this week, Brightstar Lottery PLC announced that its subsidiaries signed a 19-year contract with Lotterywest to supply a new central gaming system, 775 retailer terminals, and a full digital offering for Western Australia’s lottery operations. Beyond the technology win, Brightstar committed to long-term local job creation, university scholarships, and broader digital capability-building in Western Australia, deepening its role as an embedded partner rather than just an infrastructure...

Kanzhun (NasdaqGS:BZ) just reshuffled its leadership bench, moving long time finance chief Phil Yu Zhang into a new Chief Strategy Officer role while elevating Yang Mu and Wenbei Wang into boardroom and finance positions. See our latest analysis for Kanzhun. The shake up comes after a strong run for the stock, with the latest share price at $20.82 and a robust year to date share price return of 52.64 percent. This suggests momentum is still building even after a softer 90 day share price...

Praxis Precision Medicines (PRAX) just cleared a key regulatory hurdle, wrapping up a Type C meeting with the FDA that reshapes its EMBRAVE3 trial for elsunersen into a leaner single arm design. See our latest analysis for Praxis Precision Medicines. The news around EMBRAVE3 lands on top of a powerful run, with Praxis delivering a roughly 44 percent 1 month share price return and a staggering 546 percent 3 month share price return, while its 1 year total shareholder return above 250 percent...

A fresh class action lawsuit has put F5 (FFIV) back in the spotlight, accusing the company of downplaying a major security breach tied to its flagship BIG-IP product and reshaping the stock’s risk profile. See our latest analysis for F5. The lawsuit caps a volatile stretch for F5, where a sharp post earnings sell off and insider share sales have kept sentiment fragile, even as product launches and AI focused partnerships hint at longer term growth optionality. While the latest share price...

In December 2025, United Natural Foods, Inc. filed a US$49.70 million shelf registration for 1,500,000 common shares tied to an ESOP-related offering and, at its Investor Day, highlighted technology-enabled ecommerce growth, AI-driven supply chain tools, and resumed stock buybacks as it pursues low-single digit sales growth and low-double digit EBITDA growth through fiscal 2028. By pairing leaner distribution center operations with an expanded retail media network and advanced digital...

Hilton Grand Vacations (HGV) just closed a $400 million securitization of its timeshare loans, a sizable financing move that boosts liquidity and gives investors fresh insight into the company’s funding costs and credit profile. See our latest analysis for Hilton Grand Vacations. The securitization lands at a moment when sentiment around Hilton Grand Vacations is perking up, with the share price at $45.34 after a strong 1 month share price return of 21.26 percent and an 18.23 percent year to...

Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and death risk in Signatera-positive stage III colorectal cancer patients, while multiple new breast cancer studies further reinforced the prognostic power of its Signatera ctDNA assays. Together with a fresh MiRaDoR collaboration in hormone receptor-positive breast cancer and updated PALLAS MRD...

Earlier in 2025, CBL & Associates Properties announced a new US$25 million stock repurchase program through November 2026 and closed nearly US$158 million in financing across three transactions, including a lower-rate US$43 million loan used to retire existing debt. These moves highlight the company’s focus on capital allocation and refinancing to potentially strengthen its balance sheet and operational flexibility. Next, we’ll examine how the new US$25 million buyback program could...

Avantor recently announced that Simon Dingemans, a veteran executive with senior roles at GSK, Goldman Sachs and Carlyle, will join its Board of Directors effective January 2, 2026. This appointment brings additional healthcare, finance and corporate governance expertise to Avantor at a time when its competitive positioning and disclosures are under scrutiny from multiple securities class action lawsuits. We’ll now examine how the addition of Simon Dingemans to Avantor’s board shapes the...

Canadian Solar’s e-STORAGE division recently agreed to supply a 204 MW / 408 MWh battery energy storage system to Vena Energy’s Tailem Bend 3 project in South Australia, which is scheduled to begin operating in 2027 under an initial five-year service and maintenance agreement. This contract marks e-STORAGE’s fourth major battery project in Australia, lifting its installed and contracted footprint in the country to about 2 GWh and underscoring the company’s growing role in grid stability and...

Tyson Foods (TSN) has quietly outperformed the broader meat sector over the past month, climbing about 10% as investors warm up to improving earnings trends and steadier demand across beef, pork, and chicken. See our latest analysis for Tyson Foods. Zooming out, that recent 10.2% 1 month share price return has only nudged Tyson Foods to a modest 4.4% 1 year total shareholder return. Investors are still treating the latest operational improvements as early stage momentum rather than a full re...

Recently, Alaska Air Group lowered its fourth-quarter earnings outlook amid operational headwinds, while also announcing new 2026 route additions from Anchorage, Portland, and Seattle Paine Field that broaden its domestic and long-haul international network. Alongside these network moves, the company is investing in Hawai'i-produced sustainable aviation fuel and elevating safety leadership, signaling a focus on long-term efficiency and risk management even as near-term profit expectations...

Earlier this year, Getty Realty Corp. reported stronger-than-expected quarterly results, raising its AFFO guidance while maintaining portfolio occupancy at 99.8% and highlighting an almost 7% dividend yield. The combination of higher cash-flow guidance, accelerated investment activity, and a balance sheet with low leverage and no major debt due until 2028 underscored the REIT’s income resilience and financial flexibility. We’ll now explore how Getty’s raised AFFO guidance and stronger...

Peloton Interactive recently posted quarterly results showing a 6% year-on-year revenue decline but beating market expectations on revenue, EPS, and adjusted operating income, while management emphasized disciplined execution ahead of new product launches like Peloton IQ. Despite this operational progress, analysts have responded cautiously, with several reiterating Hold or Neutral ratings as they factor in higher churn, softer full-year guidance, and ongoing retail sector challenges. We’ll...